source
- Avalyn Pharma raises $300M in IPO to fund inhalable lung-fibrosis drugsAvalyn Pharma completed a $300 million initial public offering, pricing 16.7 million shares at $18 each and exceeding its original $200 million target. The proceeds will be used to develop inhalab…
- XTL Bio to acquire Psyga Bio, adding psychedelic manufacturing capabilityXTL Bio announced it will acquire all outstanding shares of Psyga Bio, a biotech focused on psychedelic therapies. The transaction gives XTL access to Psyga’s manufacturing facility, expanding its…